PT2359853E - Composições farmacêuticas e métodos úteis para a modulação da angiogénese - Google Patents

Composições farmacêuticas e métodos úteis para a modulação da angiogénese

Info

Publication number
PT2359853E
PT2359853E PT100124577T PT10012457T PT2359853E PT 2359853 E PT2359853 E PT 2359853E PT 100124577 T PT100124577 T PT 100124577T PT 10012457 T PT10012457 T PT 10012457T PT 2359853 E PT2359853 E PT 2359853E
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
methods useful
modulating angiogenesis
angiogenesis
mammalian tissue
Prior art date
Application number
PT100124577T
Other languages
English (en)
Inventor
Gera Neufeld
Zahava Vadasz
Stela Gengrovitch
Gal Akiri
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Publication of PT2359853E publication Critical patent/PT2359853E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT100124577T 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para a modulação da angiogénese PT2359853E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08

Publications (1)

Publication Number Publication Date
PT2359853E true PT2359853E (pt) 2013-12-26

Family

ID=22837793

Family Applications (4)

Application Number Title Priority Date Filing Date
PT100124585T PT2359854E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para a modulação da angiogénese
PT08020754T PT2078531E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para modular a angiogénese
PT100124577T PT2359853E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para a modulação da angiogénese
PT01958338T PT1315519E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para tratamento de cancro e fibrose hepática

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT100124585T PT2359854E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para a modulação da angiogénese
PT08020754T PT2078531E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para modular a angiogénese

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT01958338T PT1315519E (pt) 2000-08-08 2001-08-07 Composições farmacêuticas e métodos úteis para tratamento de cancro e fibrose hepática

Country Status (10)

Country Link
EP (4) EP1315519B1 (pt)
AT (1) ATE493147T1 (pt)
AU (1) AU2001280056A1 (pt)
CY (3) CY1111869T1 (pt)
DE (1) DE60143754D1 (pt)
DK (4) DK1315519T3 (pt)
ES (4) ES2440932T3 (pt)
HK (3) HK1131912A1 (pt)
PT (4) PT2359854E (pt)
WO (1) WO2002011667A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
FR2855968B1 (fr) 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
EP1706139A4 (en) 2004-01-23 2009-06-17 Massachusetts Eye & Ear Infirm LYSYL OXIDASE-LIKE 1 (LOXL1) AND ELASTOGENESIS
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
DE102007051006A1 (de) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stabile, synergistische Mischungen
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
WO2011022667A2 (en) 2009-08-21 2011-02-24 Arresto Biosciences, Inc Catalytic domains from lysyl oxidase and loxl2
AU2011212830B2 (en) 2010-02-04 2014-05-22 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
AU2001261194A1 (en) * 2000-05-03 2001-11-12 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
ES2358581T3 (es) 2011-05-12
EP1315519A2 (en) 2003-06-04
WO2002011667A2 (en) 2002-02-14
PT1315519E (pt) 2011-03-17
CY1114734T1 (el) 2016-12-14
EP2078531B1 (en) 2012-05-30
PT2078531E (pt) 2012-08-06
EP1315519A4 (en) 2005-09-14
EP2359854A1 (en) 2011-08-24
DK1315519T3 (da) 2011-04-11
EP2078531A3 (en) 2010-01-20
ES2440932T3 (es) 2014-01-31
ATE493147T1 (de) 2011-01-15
CY1111869T1 (el) 2015-11-04
HK1131912A1 (en) 2010-02-12
DK2359853T3 (da) 2013-12-09
DE60143754D1 (de) 2011-02-10
EP1315519B1 (en) 2010-12-29
DK2078531T3 (da) 2012-09-10
EP2359853A1 (en) 2011-08-24
ES2387329T3 (es) 2012-09-20
CY1113142T1 (el) 2016-04-13
DK2359854T3 (da) 2013-11-04
EP2359853B1 (en) 2013-11-06
HK1161113A1 (en) 2012-08-24
AU2001280056A1 (en) 2002-02-18
EP2078531A2 (en) 2009-07-15
EP2359854B1 (en) 2013-10-09
HK1161115A1 (en) 2012-08-24
PT2359854E (pt) 2013-11-22
ES2437093T3 (es) 2014-01-08
WO2002011667A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
HK1131912A1 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis
CY1115583T1 (el) Σκευασμα που περιλαμβανει μεταλλαγμα/τα της λυσοσωμικης αλφα-γαλακτοσιδασης α για τη θεραπευτικη αντιμετωπιση της νοσου fabry
AU7213698A (en) The use of fumaric acid derivatives
GR3032673T3 (en) Use of an effective quantitiy of active substances for the treatment of mixed skin.
EP0527801A4 (en) Thiophene sulfonamides useful as carbonic anydrase inhibitors
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
IL150981A0 (en) Kahalalide derivatives and pharmaceutical compositions containing the same
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
HU9501801D0 (en) Lactame-compounds as pharmaceutical active component
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
ATE231388T1 (de) Lang wirksames mittel zur rektalen verabreichung
AU6932691A (en) Administration method of antithrombin
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
ATE297749T1 (de) Verwendung von peptidischen bradykinin- antagonisten zur herstellung von arzneimitteln
FR2772616B1 (fr) Composition depigmentante
IL132504A0 (en) Methods for reducing fibrinogen
EP0721781A3 (en) Reduction of adipose tissue by using collagenase